"instanceType","uuid:ID","description","id","rationale","label","name"
"StudyDesign","1023a4ab-0f68-4cd2-92ea-f8f3dc673ce3","The main design for the study","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","Study Design 1"
